· SME · NSE
Price Band
₹0–0
Lot Size
0 shares
Issue Size
Min. Investment
₹0
Indicative, updates through the day
Cap price plus current GMP: ₹0 — arithmetic, not a forecast
Subscription data will appear once bidding opens.
Pramodini Medicare IPO is an SME issue opening for subscription on 12 August 2026, listing on NSE. The issue is priced at ₹0–₹0 per share, and its total size is yet to be confirmed.
No meaningful grey market premium is being quoted for Pramodini Medicare right now. For an SME issue still to open, that is common until anchor demand and subscription build — a missing premium is not the same as a negative one, and for a large issue it says more about supply than about the company. More on what the number does and does not mean is in our guide to IPO GMP, or see today’s IPO GMP for every live issue.
The lot size and minimum application will be confirmed in the prospectus. Allotment is handled by Purva Sharegistry (India) Pvt. Ltd., with the basis of allotment expected on 17 August 2026 and listing on 19 August 2026. You can later checkallotment status on the registrar’s website using your PAN or application number; if you are not allotted, the funds blocked under ASBA are released rather than debited. The full process is in our guide to IPO allotment.
Figures update through the day and are drawn from exchange and registrar data. Nothing here is investment advice; grey market premium is an unofficial indicator and we are not SEBI-registered analysts.
Incorporated in 2000, Pramodini Medicare Limited is a diagnostic service provider in India offering technology-enabled diagnostic services across radiology, clinical laboratory, and nuclear medicine segments. The company provides services to public hospitals, private hospitals, public sector undertakings (PSUs), medical colleges, and private diagnostic centres across tier I, II, and III cities. Its service portfolio includes radiology services such as MRI, CT scans, X-ray, ultrasound with colour doppler, mammography, Dexa scan, and interventional radiology; clinical laboratory services including haematology, microbiology, immunology, pathology, and biochemistry; and nuclear medicine services such as PET-CT, SPECT, and nuclear therapy. The company also operates a 24×7 teleradiology unit from Vijayawada and a processing laboratory at the same location. The business operates through four models: public-private partnership (PPP) with government hospitals and teaching institutions, private-private partnerships with hospitals, strategic partnerships with PSUs, and standalone private diagnostic centres. As of August 04, 2026, the company operated 16 diagnostic centres across seven states. As of March 31, 2026, the company had 161permanent employees.
| Category | Shares Offered | % |
|---|---|---|
| QIB | 25,32,000 | 45.91% |
| − Anchor Investor | 13,60,800 | 0% |
| − QIB (Ex. Anchor) | 11,71,200 | 0% |
| NII (HNI) | 9,60,000 | 17.41% |
| − bNII > ₹10L | 6,39,600 | 0% |
| − sNII < ₹10L | 3,20,400 | 0% |
| Retail | 20,23,200 | 36.68% |
| Market Maker | 3,36,000 | 0% |
EPS (Pre IPO)
6.02
EPS (Post IPO)
7.60
ROE
32.69%
P/E (Pre IPO)
P/E (Post IPO)
Price / Book
Market Cap
-
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Modern Diagnostic & Research Centre Ltd. | 11.04 | ₹36.89 Cr | |
| Invicta Diagnostic Ltd. | 14.51 | ₹28.12 Cr | |
| Gaudium IVF & Women Health Ltd. | 25.36 | ₹165.00 Cr | |
| Nephrocare Health Services Ltd. | 63.52 | ₹871.05 Cr |
Pramodini Medicare Ltd. Address
Purva Sharegistry (India) Pvt. Ltd.